🌟 Levocetirizine Dihydrochloride (CAS 130018-87-0) - Product Overview
Levocetirizine Dihydrochloride is a third-generation H1-receptor antagonist (molecular formula: C₂₁H₂₅ClN₂O₃·2HCl, MW: 461.81) designed to treat allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. As the R-enantiomer of cetirizine, it demonstrates enhanced efficacy and safety with rapid onset (1-3 hours) and 24-hour duration of action. This white to off-white crystalline powder (HPLC purity ≥99%) is stable under 2-8°C storage, making it ideal for pharmaceutical formulations.
🔑 Key Advantages
✔️ High Potency: Targets H1-receptors with >2x higher affinity than (S)-cetirizine, reducing histamine-driven symptoms effectively.
✔️ Rapid Relief: Achieves peak plasma concentration within 1-3 hours, offering fast symptom control.
✔️ Safety Profile: Minimal sedation risk compared to first-generation antihistamines.
✔️ Solubility: Water solubility ≥23 mg/mL for easy formulation.
📋 Applications
Allergy Management: First-line therapy for allergic rhinitis and chronic urticaria.
Research: Tool for studying histamine receptor mechanisms and enantiomer-specific drug effects.
Drug Development: Used in oral tablets, syrups, and pediatric formulations.
🏅 Quality Certifications
Complies with USP/EP pharmacopeial standards.
Rigorously tested via HPLC (≥99%), GC, and NMR for batch consistency.
Produced in GMP-certified facilities with ISO 9001 compliance.
📈 Market Insights
The global antihistamine market is projected to grow at 6.2% CAGR through 2030, driven by rising allergy prevalence. Levocetirizine holds >25% market share in prescription H1 antagonists, favored for its enantiomeric purity and safety.
China
